eNose could spare lung cancer patients negative side effects of immunotherapy

Mail Online | 9/17/2019 | Connor Boyd Health Reporter For Mailonline
LordLord (Posted by) Level 4
Click For Photo: https://i.dailymail.co.uk/1s/2019/09/17/12/18575846-0-image-a-15_1568720791721.jpg

An electronic nose could spare thousands of lung cancer patients from enduring brutal side effects of immunotherapy, scientists say.

A trial of the gadget found it could sniff out whether patients will have an adverse reaction to the pioneering drugs with 85 per cent accuracy.

Patients - Device - AI - Minute - Patient

Patients breathe into the device, which then uses AI and takes just one minute and to identify whether or not the patient is likely to respond to immunotherapy.

Lung cancer kills 36,000 Britons every year and around 50,000 are diagnosed with the disease annually.

Sufferers - Immunotherapy - Drugs - Patients - Immune

Sufferers can be treated with immunotherapy drugs, which utilise patients' own immune system to fight back and destroy cancer cells.

While the medicines tend to have fewer side effects than chemotherapy, they can sometimes cause the immune system attacking healthy cells.

Muscle - Aches - Shortness - Breath - Headaches

This can cause muscle aches, shortness of breath, headaches, diarrhoea and flu-like symptoms.

In very rare cases the drugs cause the immune system to go into overdrive and attack vital organs.

Dutch - Researchers - 'eNose - Compounds - VOCs

Dutch researchers say the 'eNose' can smell volatile organic compounds (VOCs), chemicals which make up about one per cent of our exhaled breath.

By detecting how many different VOCs are in the lungs, the device is able to predict whether the patients will respond to the drugs.

Immunotherapy - Drugs - Protein - Death - Ligand

Immunotherapy drugs attack a protein that is called programmed death ligand 1 (PD-L1) - but they are only effective on 20 per cent of patients.

The protein is thought to dampen and weaken the immune system when non-small cell lung cancer - the most common lung cancer - strikes.

Immunohistochemistry - Test - Treatment - Medics - Lung

Immunohistochemistry is the only test available to predict who will benefit from the treatment but it requires medics looking at lung tissue to spot the protein.

Michel van den Heuvel, who led the research at Radboud University Medical Centre, warned it is invasive and takes too long to obtain results.


The researchers...
(Excerpt) Read more at: Mail Online
Wake Up To Breaking News!
Warum denn nicht?
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!